Target Localization and Toxicity in Dose-Escalated Prostate Radiotherapy with Image-Guided Approach using Daily Planar Kilovoltage Imaging

被引:4
|
作者
Nath, S. K. [1 ,4 ]
Sandhu, A. P. [1 ]
Sethi, R. A. [1 ]
Jensen, L. G. [1 ,4 ]
Rosario, M. D. [1 ]
Kane, C. J. [2 ]
Parsons, J. K. [2 ]
Millard, F. E. [3 ]
Jiang, S. B. [1 ,4 ]
Rice, R. K. [1 ]
Pawlicki, T. [1 ]
Mundt, A. J. [1 ,4 ]
机构
[1] Univ Calif San Diego, Dept Radiat Oncol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Surg, Div Urol Oncol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Med, Div Hematol & Oncol, Moores Comprehens Canc Ctr, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Ctr Adv Radiotherapy Technol, La Jolla, CA 92093 USA
关键词
Acute toxicity; Image guided radiotherapy; Late toxicity; On-board imaging; Prostate cancer; MODULATED RADIATION-THERAPY; BEAM COMPUTED-TOMOGRAPHY; REAL-TIME TRACKING; ACUTE GENITOURINARY; CANCER; SYSTEM; IMRT; CT; ULTRASOUND; EXPERIENCE;
D O I
10.7785/tcrt.2012.500177
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dose escalation with intensity-modulated radiation therapy (IMRT) for carcinoma of the prostate has augmented the need for accurate prostate localization prior to dose delivery. Daily planar kilovoltage (kV) imaging is a low-dose image-guidance technique that is prevalent among radiation oncologists. However, clinical outcomes evaluating the benefit of daily kV imaging are lacking. The purpose of this study was to report our clinical experience, including prostate motion and gastrointestinal (GI) and genitourinary (GU) toxicities, using this modality. A retrospective analysis of 100 patients treated consecutively between December 2005 and March 2008 with definitive external beam IMRT for T1c-T4 disease were included in this analysis. Prescription doses ranged from 74-78 Gy (median, 76) in 2 Gy fractions and were delivered following daily prostate localization using on-board kV imaging (OBI) to localize gold seed fiducial markers within the prostate. Acute and late toxicities were graded as per the NCI CTCAEv3.0. The median follow-up was 22 months. The magnitude and direction of prostate displacement and daily shifts in three axes are reported. Of note, 9.1% and 12.9% of prostate displacements were >= 5 mm in the anterior-posterior and superior-inferior directions, respectively. Acute grade 2 GI and GU events occurred in 11% and 39% of patients, respectively, however no grade 3 or higher acute GI or GU events were observed. Regarding late toxicity, 2% and 17% of patients developed grade 2 toxicities, and similarly no grade 3 or higher events had occurred by last follow-up. Thus, kV imaging detected a substantial amount of inter-fractional displacement and may help reduce toxicity profiles, especially high grade events, by improving the accuracy of dose delivery.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 50 条
  • [1] Rectal retractor application during image-guided dose-escalated prostate radiotherapy
    Mahdavi, Seied Rabi
    Ghaffari, Hamed
    Mofid, Bahram
    Rostami, Aram
    Reiazi, Reza
    Janani, Leila
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (10) : 923 - 933
  • [2] CLINICAL OUTCOME OF DOSE-ESCALATED IMAGE-GUIDED RADIOTHERAPY FOR SPINAL METASTASES
    Guckenberger, Matthias
    Goebel, Joachim
    Wilbert, Juergen
    Baier, Kurt
    Richter, Anne
    Sweeney, Reinhart A.
    Bratengeier, Klaus
    Flentje, Michael
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 828 - 835
  • [3] Improving Toxicity Profiles with Dose-Escalated Image-Guided Radiation Therapy in Patients with Localized Prostate Cancer
    Burkeen, J.
    Hopper, A. B.
    Sandhu, A. P. S.
    Moiseenko, V.
    Mundt, A. J., Jr.
    Kane, C. J.
    Parsons, J. K.
    Derweesh, I.
    Kader, K.
    Einck, J. P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E217 - E217
  • [4] Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy
    Byrne, K.
    Hruby, G.
    Kneebone, A.
    Whalley, D.
    Guo, L.
    McCloud, P.
    Eade, T.
    [J]. CLINICAL ONCOLOGY, 2017, 29 (09) : 617 - 625
  • [5] Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy
    Tomasz Barelkowski
    Peter Wust
    David Kaul
    Sebastian Zschaeck
    Waldemar Wlodarczyk
    Volker Budach
    Pirus Ghadjar
    Marcus Beck
    [J]. Strahlentherapie und Onkologie, 2020, 196 : 229 - 242
  • [6] Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy
    Barelkowski, Tomasz
    Wust, Peter
    Kaul, David
    Zschaeck, Sebastian
    Wlodarczyk, Waldemar
    Budach, Volker
    Ghadjar, Pirus
    Beck, Marcus
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (03) : 229 - 242
  • [7] SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: A DOSE-ESCALATED, TARGET-GUIDED APPROACH
    Zilli, T.
    Peguret, N.
    Vees, H.
    Rouzaud, M.
    Dipasquale, G.
    Nouet, P.
    Buchegger, F.
    Khan, H. G.
    Miralbell, R.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (08) : 531 - 531
  • [8] Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
    Marina, Ovidiu
    Gustafson, Gary S.
    Kestin, Larry L.
    Brabbins, Donald S.
    Chen, Peter Y.
    Ye, Hong
    Martinez, Alvaro A.
    Ghilezan, Michel I.
    Wallace, Michelle
    Krauss, Daniel J.
    [J]. BRACHYTHERAPY, 2014, 13 (01) : 59 - 67
  • [9] Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
    Rosenbrock, Johannes
    Baues, Christian
    Kreis, Marius
    Fouassi, Redouane
    Celik, Eren
    Paffenholz, Pia
    Pfister, David
    Heidenreich, Axel
    Marnitz, Simone
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (06) : 574 - 584
  • [10] Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
    Johannes Rosenbrock
    Christian Baues
    Marius Kreis
    Redouane Fouassi
    Eren Celik
    Pia Paffenholz
    David Pfister
    Axel Heidenreich
    Simone Marnitz
    [J]. Strahlentherapie und Onkologie, 2023, 199 : 574 - 584